Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

• المؤلفون الرئيسيون: Cressey T., Hazra R., Wiznia A., Foca M., Jean-Philippe P., Graham B., King J., Britto P., Carey V., Acosta E., Yogev R.
• التنسيق: دورية
• منشور في: 2017
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84984700603&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/41295

© 2016 Wolters Kluwer Health, Inc. All rights reserved. HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a com...